About us
Mission
Value
Team
Team
Board of Directors
Advisors
Contact us
Science
Pipline
ART-001
ART-648
News
日本語
English
News Release
Posted date:
2021.06.30
We are pleased to announce that Dr. Victor Stone from Takeda Ventures was elected and appointed as a new director at our Ordinary General Meeting of Shareholders on June 16, 2021.
Posted date:
2021.06.30
Website updated.
Recent Posts
ARTham Therapeutics Presents Data from Phase 2 Study of ART-001 at International Conference on Vascular Anomalies 2023
ART-001 phase II study met its primary endpoint of response rate in patients with slow-flow vascular malformations
Kaken Pharmaceutical to acquire ARTham Therapeutics
ARTham announces first patient dosed in Phase 2 clinical trial of ART-648 in patients with bullous pemphigoid.
ARTham announces first patient dosed in Phase 2 clinical trial of ART-001 in patients with slow-flow vascular malformations.
Archives
2022.12
2021.11
2021.10
2021.08
2021.06
2021.03
2021.01
2020.09
2020.08
2020.03
2019.02
2018.12
Home
About us
ミッション
企業理念
チーム
チーム
取締役
アドバイザー
お問い合わせ
Science
パイプライン
ART-001
ART-648
News
Home
About us
Mission
Value
Team
Team
Board of Directo
Advisors
Contact us
Science
Pipeline
ART-001
ART-648
News